1. Home
  2. PRTA vs AACT Comparison

PRTA vs AACT Comparison

Compare PRTA & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • AACT
  • Stock Information
  • Founded
  • PRTA 2012
  • AACT 2021
  • Country
  • PRTA Ireland
  • AACT United States
  • Employees
  • PRTA N/A
  • AACT N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • AACT
  • Sector
  • PRTA Health Care
  • AACT
  • Exchange
  • PRTA Nasdaq
  • AACT Nasdaq
  • Market Cap
  • PRTA 809.8M
  • AACT 697.5M
  • IPO Year
  • PRTA N/A
  • AACT 2023
  • Fundamental
  • Price
  • PRTA $7.18
  • AACT $11.29
  • Analyst Decision
  • PRTA Buy
  • AACT
  • Analyst Count
  • PRTA 9
  • AACT 0
  • Target Price
  • PRTA $51.71
  • AACT N/A
  • AVG Volume (30 Days)
  • PRTA 1.6M
  • AACT 596.2K
  • Earning Date
  • PRTA 05-08-2025
  • AACT 01-01-0001
  • Dividend Yield
  • PRTA N/A
  • AACT N/A
  • EPS Growth
  • PRTA N/A
  • AACT 15.24
  • EPS
  • PRTA N/A
  • AACT 1.81
  • Revenue
  • PRTA $137,935,000.00
  • AACT N/A
  • Revenue This Year
  • PRTA N/A
  • AACT N/A
  • Revenue Next Year
  • PRTA $122.59
  • AACT N/A
  • P/E Ratio
  • PRTA N/A
  • AACT $6.24
  • Revenue Growth
  • PRTA 54.55
  • AACT N/A
  • 52 Week Low
  • PRTA $8.00
  • AACT $10.58
  • 52 Week High
  • PRTA $25.42
  • AACT $11.29
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 30.36
  • AACT 62.60
  • Support Level
  • PRTA $6.47
  • AACT $11.26
  • Resistance Level
  • PRTA $8.08
  • AACT $11.29
  • Average True Range (ATR)
  • PRTA 0.72
  • AACT 0.02
  • MACD
  • PRTA 0.00
  • AACT -0.00
  • Stochastic Oscillator
  • PRTA 21.60
  • AACT 87.50

About PRTA Prothena Corporation plc

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

About AACT Ares Acquisition Corporation II

Ares Acquisition Corp II is a blank check company.

Share on Social Networks: